As mentioned, the pattern of NF-κB pathway mutations in PMBL is similar to that observed in cHL and largely different from the one characterizing ABC-DLBCL, in that activating mutations of upstream BCR pathway molecules (such as CD79 and CARD11) or TLR pathway components (MYD88) do not occur. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.